CorMedix gets FDA priority review for Rezzayo label expansion
FROM THE WIRE · SEEKINGALPHA.COM
[US Food and Drug Administration (FDA)] * CorMedix (CRMD [https://seekingalpha.com/symbol/CRMD]) on Monday announced that the Food and Drug Administration granted priority review for its marketing application seeking a label expansion for its antifungal therapy Rezzayo, marketed…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishFDA priority review could support the stock if the label expansion is approved favorably.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA granted priority review of the supplemental application for Rezzayo.
- 02The request covers prophylaxis of invasive fungal disease with a once-weekly injection.
- 03The FDA decision is expected in Q1 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets